Skip to main content
Premium Trial:

Request an Annual Quote

Codex DNA Partners With RNAimmune on mRNA Synthesis Technologies

NEW YORK — Codex DNA has partnered with biopharmaceutical firm RNAimmune on the development of new mRNA synthesis kits, the companies said on Monday.

Under the terms of the deal, RNAimmune will evaluate and validate technologies for automated mRNA synthesis and delivery under development at San Diego-based Codex DNA.

Additional terms were not disclosed.

"Our partnership with Codex DNA can enhance their highly automated solutions for mRNA production," Dong Shen, RNAimmune's founder and president, said in a statement. "Together, we can incorporate our proprietary carrier molecules into Codex DNA's mRNA synthesis kits to improve automated production toward truly transfection-ready mRNA with enhanced uptake and expression."

Newly public Codex DNA, which develops benchtop synthetic biology systems, said that its mRNA synthesis technologies are expected to help in the discovery and development of new mRNA vaccines and therapeutics.

"We look forward to working with the RNAimmune team to validate our highly functional mRNA synthesis kits and potentially integrate RNAimmune's proprietary mRNA delivery solutions into our automated workflows," Codex DNA CEO Todd Nelson said in the statement.